Physician profile
Brian D Long
NPI 1760446181
$3,824.89
in general payments reported to CMS, 2019-2025
21 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $374 · 2021: $763 · 2022: $511 · 2023: $495 · 2024: $526 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.06 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,012.79 | 2019-2025 | Clareon, Lensx, Verion |
| Allergan, INC. | $366.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $363.27 | 2019-2023 | |
| Abbvie INC. | $259.29 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $243.70 | 2019-2025 | Tecnis Simplicity, Veritas Vision System |
| Bausch & Lomb Americas INC. | $223.80 | 2023-2025 | Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $215.87 | 2019-2021 | |
| Glaukos Corporation | $163.61 | 2021-2023 | |
| Medtronic Vascular, INC. | $143.23 | 2019 | |
| Horizon Therapeutics Plc | $132.98 | 2019-2021 | |
| Harrow Eye, LLC | $130.08 | 2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $116.05 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $112.77 | 2020-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.81 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $78.74 | 2024-2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $52.05 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $40.08 | 2019-2020 | |
| Amgen INC. | $28.34 | 2025 | Tepezza |
| Rxsight INC | $23.52 | 2022 | |
| Astellas Pharma US INC | $17.73 | 2019 | |
| Thea Pharma INC. | $15.71 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.